tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2022 Jan 26;28(3).
doi: 10.3201/eid2803.212299. Online ahead of print.
High-Dose Convalescent Plasma for Treatment of Severe COVID-19
Gil C De Santis, Luciana Correa Oliveira, Pedro M M Garibaldi, Carlos E L Almado, Julio Croda, Ghislaine G A Arcanjo, Érika A F Oliveira, Adriana C Tonacio, Dante M Langhi Jr, José O Bordin, Renato N Gilio, Leonardo C Palma, Elaine V Santos, Simone K Haddad, Benedito P A Prado Jr, Marjorie Cornejo Pontelli, Rogério Gomes, Carlos H Miranda, Maria Auxiliadora Martins, Dimas T Covas, Eurico Arruda, Benedito A L Fonseca, Rodrigo T Calado
Abstract
To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19.
Keywords: 2019 novel coronavirus disease; Brazil; COVID-19; SARS-CoV-2; convalescent plasma; coronavirus disease; neutralizing antibody; passive immunization; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
. 2022 Jan 26;28(3).
doi: 10.3201/eid2803.212299. Online ahead of print.
High-Dose Convalescent Plasma for Treatment of Severe COVID-19
Gil C De Santis, Luciana Correa Oliveira, Pedro M M Garibaldi, Carlos E L Almado, Julio Croda, Ghislaine G A Arcanjo, Érika A F Oliveira, Adriana C Tonacio, Dante M Langhi Jr, José O Bordin, Renato N Gilio, Leonardo C Palma, Elaine V Santos, Simone K Haddad, Benedito P A Prado Jr, Marjorie Cornejo Pontelli, Rogério Gomes, Carlos H Miranda, Maria Auxiliadora Martins, Dimas T Covas, Eurico Arruda, Benedito A L Fonseca, Rodrigo T Calado
- PMID: 35081022
- DOI: 10.3201/eid2803.212299
Abstract
To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19.
Keywords: 2019 novel coronavirus disease; Brazil; COVID-19; SARS-CoV-2; convalescent plasma; coronavirus disease; neutralizing antibody; passive immunization; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.